Small Molecules
Developing and validating rugged methods for optimizing small molecule drug development study execution is pivotal in the journey toward regulatory approvals. A methodic approach not only ensures consistency and reliability in data, but also empowers you to make informed decisions, enhancing the efficiency and success of your project.
Aliri has implemented a robust approach, including 7 crucial steps below, to help you navigate the complexities and uncertainties that come with advancing small molecules for drug development.
- MS Tuning
- HPLC Separation
- Sample Preparation
- Stability
- Matix Effects
- Moving from method development into method validation
- Moving from method validation into sample analysis

Large Molecules
Large molecule drugs require advanced bioanalytical support, and Aliri is proud to offer robust experience and solutions that leverage LC-MS/MS and HRMS (high-resolution mass spectrometry), including:
- Vast biologic diversity spanning from small (1 kDA) therapeutic peptides to large (900 kDA IgM) proteins
- A wide range of sample preparation methods — simple protein precipitation to complex affinity capture enrichment techniques
- Development and validation of mass spectrometry assays using surrogate peptides produced by proteolytic digestion of proteins for quantification
- Semi-quantitative analysis of intact proteins (>10 kDA) molecule projects